Nisa Investment Advisors LLC Lowers Stock Holdings in Boston Scientific Corporation $BSX

Nisa Investment Advisors LLC cut its holdings in Boston Scientific Corporation (NYSE:BSX) by 5.5% in the second quarter, Holdings Channel reports. The institutional investor owned 383,813 shares of the medical equipment provider’s stock after selling 22,142 shares during the quarter. Nisa Investment Advisors LLC’s holdings in Boston Scientific were worth $41,225,000 at the end of the most recent reporting period.

Other institutional investors have also recently added to or reduced their stakes in the company. GAMMA Investing LLC raised its position in Boston Scientific by 15.4% during the second quarter. GAMMA Investing LLC now owns 29,486 shares of the medical equipment provider’s stock worth $3,167,000 after acquiring an additional 3,932 shares during the period. MRA Advisory Group purchased a new stake in shares of Boston Scientific during the second quarter worth about $273,000. Bank of New Hampshire raised its position in shares of Boston Scientific by 552.0% during the 2nd quarter. Bank of New Hampshire now owns 19,724 shares of the medical equipment provider’s stock worth $2,119,000 after purchasing an additional 16,699 shares during the last quarter. NS Partners Ltd lifted its stake in Boston Scientific by 1.6% in the 1st quarter. NS Partners Ltd now owns 368,189 shares of the medical equipment provider’s stock valued at $37,143,000 after buying an additional 5,704 shares in the last quarter. Finally, New England Research & Management Inc. acquired a new stake in Boston Scientific in the 2nd quarter worth about $1,133,000. Institutional investors and hedge funds own 89.07% of the company’s stock.

Analyst Ratings Changes

A number of equities analysts have commented on BSX shares. Canaccord Genuity Group reissued a “buy” rating and set a $132.00 target price on shares of Boston Scientific in a report on Thursday. Oppenheimer upgraded Boston Scientific from a “market perform” rating to an “outperform” rating and lifted their price target for the stock from $118.00 to $125.00 in a report on Monday, September 8th. The Goldman Sachs Group restated a “buy” rating and set a $124.00 price objective on shares of Boston Scientific in a research report on Wednesday. Jefferies Financial Group restated a “hold” rating on shares of Boston Scientific in a report on Monday, July 21st. Finally, UBS Group upped their price objective on Boston Scientific from $135.00 to $140.00 and gave the company a “buy” rating in a report on Thursday. Two investment analysts have rated the stock with a Strong Buy rating, twenty-one have given a Buy rating and two have assigned a Hold rating to the company. According to data from MarketBeat, the company presently has a consensus rating of “Buy” and an average price target of $123.77.

Boston Scientific Stock Down 1.3%

Boston Scientific stock opened at $101.08 on Friday. The stock has a market cap of $149.78 billion, a PE ratio of 54.06, a P/E/G ratio of 2.34 and a beta of 0.61. The company has a debt-to-equity ratio of 0.49, a current ratio of 1.37 and a quick ratio of 0.82. The stock’s fifty day moving average is $101.14 and its two-hundred day moving average is $102.08. Boston Scientific Corporation has a 1-year low of $80.64 and a 1-year high of $109.50.

Boston Scientific (NYSE:BSX) last issued its earnings results on Wednesday, October 22nd. The medical equipment provider reported $0.75 earnings per share for the quarter, topping the consensus estimate of $0.71 by $0.04. The business had revenue of $5.07 billion for the quarter, compared to analyst estimates of $4.97 billion. Boston Scientific had a return on equity of 19.74% and a net margin of 14.43%.The business’s quarterly revenue was up 20.3% on a year-over-year basis. During the same quarter last year, the company earned $0.63 EPS. Boston Scientific has set its FY 2025 guidance at 3.020-3.040 EPS. Q4 2025 guidance at 0.770-0.790 EPS. On average, sell-side analysts expect that Boston Scientific Corporation will post 2.85 EPS for the current fiscal year.

Insider Activity at Boston Scientific

In other Boston Scientific news, EVP Joseph Michael Fitzgerald sold 50,000 shares of the firm’s stock in a transaction dated Wednesday, October 1st. The shares were sold at an average price of $98.47, for a total transaction of $4,923,500.00. Following the sale, the executive vice president directly owned 178,342 shares of the company’s stock, valued at $17,561,336.74. This trade represents a 21.90% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, EVP Arthur C. Butcher sold 17,313 shares of the business’s stock in a transaction that occurred on Friday, August 1st. The shares were sold at an average price of $104.63, for a total transaction of $1,811,459.19. Following the completion of the sale, the executive vice president owned 23,600 shares of the company’s stock, valued at approximately $2,469,268. The trade was a 42.32% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 170,214 shares of company stock valued at $17,548,337 in the last three months. 0.50% of the stock is currently owned by company insiders.

Boston Scientific Profile

Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. It operates through two segments, MedSurg and Cardiovascular. The company offers devices to diagnose and treat gastrointestinal and pulmonary conditions, such as resolution clips, biliary stent systems, stents and electrocautery enhanced delivery systems, direct visualization systems, digital catheters, and single-use duodenoscopes; devices to treat urological conditions, including ureteral stents, catheters, baskets, guidewires, sheaths, balloons, single-use digital flexible ureteroscopes, holmium laser systems, artificial urinary sphincter, laser system, fiber, and hydrogel systems; and devices to treat neurological movement disorders and manage chronic pain, such as spinal cord stimulator system, proprietary programming software, radiofrequency generator, indirect decompression systems, practice optimization tools, and deep brain stimulation system.